首页> 外文期刊>International Journal of Molecular Sciences >Therapeutic Targeting Steroid Resistant Pro-Inflammatory NK and NKT-Like Cells in Chronic Inflammatory Lung Disease
【24h】

Therapeutic Targeting Steroid Resistant Pro-Inflammatory NK and NKT-Like Cells in Chronic Inflammatory Lung Disease

机译:靶向治疗类固醇的抗炎性NK和NKT样细胞在慢性炎性肺疾病中的作用

获取原文
           

摘要

The innate immune system drives the initiation of inflammation and progression to chronic inflammation in two important chronic inflammatory lung diseases involving the small airways, chronic obstructive pulmonary disease (COPD) and bronchiolitis obliterans syndrome (BOS), following lung transplantation. Recently natural killer T cell like (NKT-like) cells, which represent a bridge between the innate and adaptive immune response as well as the innate natural killer cell (NK) cells, have been shown to be important cells in these two chronic lung diseases. Importantly these cells have been shown to be resistant to commonly used anti-inflammatory drugs such as glucocorticoids and as such their inflammatory nature has been difficult to suppress. Mechanisms leading to steroid resistance in both diseases has recently been shown. Glucocorticoids switch off inflammatory genes by first entering the cell and binding to glucocorticoid receptors (GCRs). The steroid-GCR complex must then be chaperoned into the nucleus via several heat shock proteins, where they engage histone deacetylase 2 to switch off pro-inflammatory gene transcription. Many of these mechanisms are altered in NK and NKT-like cells in COPD and BOS requiring novel intervention using combinations of currently available drugs. Evidence will be presented to show how these drugs can overcome these mechanisms of drug resistance ex vivo advising novel therapeutic strategies for the treatment these two important chronic inflammatory lung diseases.
机译:在肺移植后,先天免疫系统在涉及小气道的两种重要的慢性炎症性肺病,慢性阻塞性肺病(COPD)和闭塞性细支气管炎综合征(BOS)中驱动炎症的发生并发展为慢性炎症。最近,天然杀伤性T细胞样(NKT样)细胞代表了先天性和适应性免疫应答之间的桥梁,以及先天性天然杀伤性细胞(NK),已被证明是这两种慢性肺病中的重要细胞。 。重要的是,这些细胞已显示出对常用的抗炎药如糖皮质激素具有抗性,因此难以抑制其炎性。最近已经证明了在两种疾病中导致类固醇抵抗的机制。糖皮质激素首先进入细胞并与糖皮质激素受体(GCR)结合,从而关闭炎症基因。然后必须通过几种热休克蛋白将类固醇-GCR复合物陪伴进入细胞核,在那里它们与组蛋白脱乙酰基酶2结合以关闭促炎基因转录。这些机制中的许多机制在COPD和BOS的NK和NKT样细胞中发生了变化,需要使用现有药物的组合进行新的干预。将提供证据来表明这些药物如何能克服体外抗药性的这些机制,并为治疗这两种重要的慢性炎症性肺病提出新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号